HELIX BIOPHARMA | 0,615 Euro | -0,001 -0,16 % | |
| WKN: 918846 ISIN: CA4229101098 Ticker-Symbol: HBP | Frankfurt | 24.05.13 | 19:45 Uhr |
Branche BiotechnologieAktienmarkt Sonstige |
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 08.04. | Helix BioPharma Corp. Announces L-DOS47 Scientific Poster to Be Presented at American Association for Cancer Research Annual Meeting in Washington, DC | 67 | Marketwired | |
| AURORA, ON -- (Marketwired) -- 04/08/13 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today... Mehr lesen zu: Helix BioPharma Corp. Announces L-DOS47 Scientific Poster to Be Presented at American Association for Cancer Research Annual Meeting in Washington, DC | ||||
| 04.04. | Helix Biopharma Corp. Initiates Enrollment for Third Cohort and Expansion of Centres in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47 | 65 | Marketwired | |
| AURORA, ON -- (Marketwired) -- 04/04/13 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer... Mehr lesen zu: Helix Biopharma Corp. Initiates Enrollment for Third Cohort and Expansion of Centres in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47 | ||||
| 18.03. | Helix BioPharma Corp. Announces L-DOS47 Scientific Presentation to Be Made at BIT LifeScience's 5th International Congress of Antibodies | 90 | Marketwired | |
| AURORA, ONTARIO -- (Marketwire) -- 03/18/13 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer,... Mehr lesen zu: Helix BioPharma Corp. Announces L-DOS47 Scientific Presentation to Be Made at BIT LifeScience's 5th International Congress of Antibodies | ||||
| 11.03. | Helix BioPharma Corp. Announces Q2 Fiscal 2013 Results | 70 | Marketwired | |
| AURORA, ON -- (Marketwire) -- 03/11/13 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today... Mehr lesen zu: Helix BioPharma Corp. Announces Q2 Fiscal 2013 Results | ||||
| 07.03. | Helix BioPharma Corp. Announces Extension of 2009 Warrant Expiry Date | 44 | Marketwired | |
| AURORA, ON -- (Marketwire) -- 03/07/13 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today... Mehr lesen zu: Helix BioPharma Corp. Announces Extension of 2009 Warrant Expiry Date | ||||
| 25.02. | Helix BioPharma Announces Director Resignation | 53 | Marketwired | |
| AURORA, ON -- (Marketwire) -- 02/25/13 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today... Mehr lesen zu: Helix BioPharma Announces Director Resignation | ||||
| 21.02. | Helix BioPharma Corp. Announces Extension of 2009 Warrant Expiry Date | 67 | Marketwired | |
| AURORA, ON -- (Marketwire) -- 02/21/13 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today... Mehr lesen zu: Helix BioPharma Corp. Announces Extension of 2009 Warrant Expiry Date | ||||
| 21.02. | Helix BioPharma Announces Appointment of Director | 42 | Marketwired | |
| AURORA, ON -- (Marketwire) -- 02/21/13 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today... Mehr lesen zu: Helix BioPharma Announces Appointment of Director | ||||
| 10.02. | Helix BioPharma Announces Director Resignation | 92 | Marketwired | |
| AURORA, ON -- (Marketwire) -- 02/10/13 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, announced... Mehr lesen zu: Helix BioPharma Announces Director Resignation | ||||
| 21.12. | Helix BioPharma Announces Appointment of Director | 102 | Marketwired | |
| AURORA, ON -- (Marketwire) -- 12/20/12 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today... Mehr lesen zu: Helix BioPharma Announces Appointment of Director | ||||
| 20.12. | Clinical Update: Helix BioPharma Corp. Completes Enrollment in First Cohort and Initiates Second Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47 | 69 | Marketwired | |
| AURORA, ON -- (Marketwire) -- 12/20/12 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer... Mehr lesen zu: Clinical Update: Helix BioPharma Corp. Completes Enrollment in First Cohort and Initiates Second Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47 | ||||
| 17.12. | Helix BioPharma Announces Director Resignations | 68 | Marketwired | |
| AURORA, ONTARIO -- (Marketwire) -- 12/17/12 -- Helix BioPharma Corp. (TSX: HBP)(FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer,... Mehr lesen zu: Helix BioPharma Announces Director Resignations | ||||
| 14.12. | Helix Biopharma And Merck Terminate Deal For TIFN Alpha-2b Development Program | 131 | AFX News | |
| WHITEHOUSE STATION (dpa-AFX) - Helix Biopharma Corp. (HBP.TO) announced that
the company and Merck & Co. Inc. (MRK) have agreed to terminate their
collaboration under the Material Transfer... Mehr lesen zu: Helix Biopharma And Merck Terminate Deal For TIFN Alpha-2b Development Program | ||||
| 14.12. | Helix BioPharma and Merck Terminate Material Transfer and License Option Agreement for Topical Interferon Alpha-2b Development Program | 2.235 | Marketwired | |
| AURORA, ON -- (Marketwire) -- 12/14/12 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today... Mehr lesen zu: Helix BioPharma and Merck Terminate Material Transfer and License Option Agreement for Topical Interferon Alpha-2b Development Program | ||||
| 13.12. | Helix BioPharma Corp. Announces Fiscal 2013 Q1 Results | 91 | Marketwired | |
| AURORA, ON -- (Marketwire) -- 12/12/12 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today... Mehr lesen zu: Helix BioPharma Corp. Announces Fiscal 2013 Q1 Results | ||||
| 10.12. | Helix BioPharma Corp. Announces Sale of Rivex Pharma Division to Pharmascience Inc. | 104 | Marketwired | |
| AURORA, ON -- (Marketwire) -- 12/10/12 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today... Mehr lesen zu: Helix BioPharma Corp. Announces Sale of Rivex Pharma Division to Pharmascience Inc. | ||||
| 25.10. | Helix BioPharma Corp. Announces Fiscal 2012 Results | 77 | Marketwired | |
| AURORA, ON -- (Marketwire) -- 10/25/12 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("HBP"), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer... Mehr lesen zu: Helix BioPharma Corp. Announces Fiscal 2012 Results | ||||
| 23.10. | Helix BioPharma Corp. Announces First Patient Enrolled and First Dose Administered in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47 | 88 | Marketwired | |
| AURORA, ON -- (Marketwire) -- 10/23/12 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("HBP"), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer... Mehr lesen zu: Helix BioPharma Corp. Announces First Patient Enrolled and First Dose Administered in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47 | ||||
| 07.09. | Helix BioPharma Corp. Announces TSX Approval of Extension of 2009 Warrant Expiry Date and Meetings With Shareholders in Poland | 59 | Marketwired | |
| AURORA, ON -- (Marketwire) -- 09/07/12 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today... Mehr lesen zu: Helix BioPharma Corp. Announces TSX Approval of Extension of 2009 Warrant Expiry Date and Meetings With Shareholders in Poland | ||||
| 19.07. | Helix BioPharma Corp. Announces Filing of Form 15F to Terminate SEC Reporting Obligations | 36 | Marketwired | |
| AURORA, ON -- (Marketwire) -- 07/19/12 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today... Mehr lesen zu: Helix BioPharma Corp. Announces Filing of Form 15F to Terminate SEC Reporting Obligations | ||||
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| MEDIGENE | 0,93 | +4,61 % | Medigene: Rating wird erneuert |
| QIAGEN | 14,66 | +1,14 % | QIAGEN Downgraded to Strong Sell |
| AGENNIX | 0,07 | -27,08 % | Agennix AG gibt Liquidation bekannt |
| NOVEMBER | 0,031 | +3,33 % | EANS-PVR: november Aktiengesellschaft / Veröffentlichung gemäß § 26 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung |
| FARMATIC BIOTECH ENERGY | 0,006 | +20 % | XFRA FRA:Deletion of Instruments from XETRA - 04.12.2012-001 |
